Memorial Sloan-Kettering investigators are also studying sorafenib (Nexavar®) for use in multiple myeloma patients with abnormal kidney function. An oral multiple kinase inhibitor that affects tumor growth and angiogenesis (blood vessel formation), sorafenib stops cancer cells from producing a signal that is necessary for their multiplication, according to research findings.
This came from the Sloan Kettering site and I'm interested because of my recent kidney problems. I'd like to talk to anyone who has been using Nexavar about their experiences with this drug. Any help gratefully appreciated. Many thanks, Cath